Company / Working Capital
Adaptive Biotechnologies Corp Working Capital History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$210.3M
FY2025
5-year range
$185.7M / $452.4M
FY2021-FY2025
Trend
+13.2%
vs FY2024
Sector context
#166 of 213
Health Care
What the data says
Adaptive Biotechnologies Corp's working capital of $210M is lower than 78% of companies in the Health Care sector (FY2025). Working Capital returned to growth in FY2025 after 2 years of decline, reaching $210M.
Based on SEC 10-K filings.
$210M in FY2025 with a 5-year CAGR of -19.5%.
Declined from $322M to $210M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -22.5%
- 5-Year CAGR
- -19.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 213This company $210.3M Sector average $934.6M
▼
-77.5% below sector average
Key checks
Key Insights
- 5-year CAGR of -19.5%, indicating a declining trend.
- In FY2025, working capital increased 13.2% year-over-year.
- Ranks #166 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -1.45 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $210.3M | +13.2% |
| FY2024 | $185.7M | -42.4% |
| FY2023 | $322.2M | -28.8% |
| FY2022 | $452.4M | +56.6% |
| FY2021 | $288.9M | -53.5% |
| FY2020 | $621.7M | +16.3% |
| FY2019 | $534.4M | +238.4% |
| FY2018 | $157.9M | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026